Glycan-Reactive Innate-like B Cells and Developmental Checkpoints.
J Stewart NewBrian L P DizonJohn F KearneyR Glenn KingPublished in: Journal of immunology (Baltimore, Md. : 1950) (2024)
Using an Ig H chain conferring specificity for N-acetyl-d-glucosamine (GlcNAc), we developed transgenic (VHHGAC39 TG) mice to study the role of self-antigens in GlcNAc-reactive B-1 B cell development. In VHHGAC39 TG mice, GlcNAc-reactive B-1 B cell development during ontogeny and in adult bone marrow was normal. However, adult TG mice exhibited a block at transitional-2 immature B cell stages, resulting in impaired allelic exclusion and accumulation of a B cell subset coexpressing endogenous Ig gene rearrangements. Similarly, VHHGAC39 B cell fitness was impeded compared with non-self-reactive VHJ558 B TG cells in competitive mixed bone marrow chimeras. Nonetheless, adult VHHGAC39 mice immunized with Streptococcus pyogenes produce anti-GlcNAc Abs. Peritoneal cavity B cells transferred from VHHGAC39 TG mice into RAG-/- mice also exhibited robust expansion and anti-GlcNAc Ab production. However, chronic treatment of young VHHGAC39 mice with GlcNAc-specific mAbs leads to lower GlcNAc-binding B cell frequencies while increasing the proportion of GlcNAc-binding B1-a cells, suggesting that Ag masking or clearance of GlcNAc Ags impedes maturation of newly formed GlcNAc-reactive B cells. Finally, BCR H chain editing promotes expression of endogenous nontransgenic BCR alleles, allowing potentially self-reactive TG B cells to escape anergy or deletion at the transitional stage of precursor B cell development. Collectively, these observations indicate that GlcNAc-reactive B cell development is sensitive to the access of autologous Ags.
Keyphrases
- bone marrow
- high fat diet induced
- mesenchymal stem cells
- induced apoptosis
- acute lymphoblastic leukemia
- type diabetes
- metabolic syndrome
- immune response
- stem cells
- insulin resistance
- physical activity
- crispr cas
- dna methylation
- gene expression
- adipose tissue
- cell death
- cell therapy
- staphylococcus aureus
- pseudomonas aeruginosa
- escherichia coli
- candida albicans
- cystic fibrosis